Monument Therapeutics, a precision neuroscience company, announced positive topline results from its Phase I clinical trial evaluating MT1988, a novel treatment targeting cognitive impairment associated with schizophrenia (CIAS). The study demonstrated favorable safety and tolerability profiles for the investigational therapy, marking a significant milestone in addressing an area of high unmet medical need.
Novel Approach to Schizophrenia Treatment
MT1988 represents a fixed-dose combination of two well-established small molecules that act on nicotinic receptors, designed to optimize safety and efficacy. The positive Phase I results support the advancement of MT1988 into Phase II clinical development, targeting CIAS and related conditions.
CIAS is a core aspect of schizophrenia that significantly impacts patients' daily functioning yet remains without approved treatment options. The condition represents a critical unmet need in psychiatric care, affecting cognitive domains essential for independent living and social functioning.
Clinical Development Progress
Monument Therapeutics first dosed a participant in its Phase I clinical study of MT1988 in November 2024. The company has been systematically building its clinical program with support from digital cognitive assessment technologies that were instrumental in the early development phases of understanding cognitive endpoints in this therapeutic area.
The precision neuroscience company has secured substantial funding to support its schizophrenia program, including £850,000 in funding led by ACF Investors with participation from Wren Capital, o2h Ventures, and angel investors in February 2025. Additionally, the company received £1 million from the Forster Foundation in October 2024 to support clinical development of MT1988.
Intellectual Property Portfolio
Monument Therapeutics has strengthened its intellectual property position for the MT1988 program with recent patent grants across multiple jurisdictions. The China National Intellectual Property Administration granted Chinese patent ZL202080036867.6 in January 2025, while the Japan Patent Office granted Japanese patent 7570345 the same month. The United States Patent and Trademark Office previously granted U.S. patent 11,862,337 in January 2024.
Strategic Leadership and Investment
The company has assembled a distinguished Scientific Advisory Board to guide its schizophrenia program, including Dr. Mark Treherne as chairperson, Dr. Stephen Brannan, and Dr. Jeff Baker. Robert S. Radie was appointed Non-Executive Chair of the Board in April 2025, with Dr. Heather Preston joining the advisory board.
Cambridge Cognition, which originally established Monument Therapeutics as an independent precision neuroscience company, retains both an equity stake and a royalty structure that entitles it to future revenues arising from commercialization of MT1988 and other programs.
Rob Baker, Joint Managing Director and Chief Operating Officer of Cambridge Cognition, commented: "We are delighted to see Monument Therapeutics achieve this significant milestone with MT1988. These promising results validate Monument's innovative approach to addressing the critical unmet need in CIAS and we remain hopeful that our investment, as well as potential future royalties, will be significantly value enhancing."
